Tildrakizumab (IL23A)

Size

£749.00

SKU:: 592253
Purity:: ≥95%
Storage Conditions:: -20°C
Supplier:: United States Biological
Host:: Human
Immunogen:: Recombinant protein corresponding to humanized IL23A [Homo sapiens], expressed in CHO cells.
Format:: Supplied as a liquid in PBS, pH 7.5.
Extra Details:: Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis 3. The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100mg at weeks 0, 4, and every 12 weeks thereafter 7. A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects 5. Applications: Suitable for use in ELISA and SDS-PAGE. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.